A new report from New York City health officials gives us a first look at the rollout of nirsevimab, a new shot designed to protect infants from RSV. The virus is a major cause of hospitalizations in babies every winter. The report focuses on infants born during the recommended time to get the shot, which is typically just before or during RSV season.
This field report describes the percentage of these eligible infants in New York City who received the protective antibody. However, the specific number or percentage is not provided in the available summary. The report also does not include any information about side effects or safety signals from this real-world use.
It's important to understand what this report is and isn't. It's an early look at a public health effort, not a formal study that measures how well the shot worked or its safety in detail. We don't know the final count of babies protected or have any comparative data. This kind of report is a first step in tracking a new public health tool, showing that the rollout happened, but leaving many questions about its actual reach and effectiveness for future research to answer.
